UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September 30,~~December 31, 2020

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39059

LOGO

AVITA ~~THERAPEUTICS,~~MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

85-1021707

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

28159 Avenue Stanford

Suite 220

Valencia, CA 91355

(Address of principal executive offices and Zip Code)

Registrant’s telephone number, including area code: (661) 367-9170

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share

RCEL

The NASDAQ Stock Market LLC

Securities registered pursuant to section 12(g) of the Act:

None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has selected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant’s $0.0001 par value common stock outstanding as of ~~November 6, 2020~~February 13, 2021 was ~~21,623,287~~21,628,633

TABLE OF CONTENTS


PART I – FINANCIAL INFORMATION		3

Item 1.	~~Financial~~Forward Looking Statements	3

	~~Balance Sheets – September 30, 2020 and June 30, 2020 (Unaudited)~~	3

	~~Statements~~Report of ~~Operations for the three and six months ended September 30, 2020 and 2019 (Unaudited)~~Independent Registered Public Accounting Firm	4

	~~Consolidated~~Financial Statements ~~of Comprehensive Loss for the three months ended September 30, 2020 and 2019 (Unaudited)~~	5

	Consolidated Balance Sheets – December 31, 2020 (unaudited) and June 30, 2020	5

	Consolidated Statements of ~~Stockholders’ Equity~~Operations for the three and six months ended ~~September 30,~~December 31, 2020 (unaudited) and 2019 ~~(Unaudited)~~	6

	Consolidated Statements of ~~Cash Flows~~Comprehensive Loss for the three and six months ended ~~September 30,~~December 31, 2020 (unaudited) and 2019 ~~(Unaudited)~~	7

	Consolidated Statements of Stockholders’ Equity for the three and six months ended December 31, 2020 unaudited) and 2019	8

	Consolidated Statements of Cash Flows for the six months ended December 31, 2020 (unaudited) and 2019	10

	Notes to Financial Statements	811

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1922

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2327

Item 4.	Controls and Procedures	2327

Part II – OTHER INFORMATION		2428

Item 1.	Legal Proceedings	2428

Item 1A.	Risk Factors	2428

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2428

Item 3.	Defaults Upon Senior Securities	2428

Item 4.	Mine Safety Disclosures	2428

Item 5.	Other Information	2428

Item 6.	Exhibits	2429

Signatures		2530

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENT

This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, the anticipated impact of the novel coronavirus, or COVID-19, pandemic on our business, business strategy, prospective products, product approvals, research and development costs, anticipated timing and likelihood of success of clinical trials, expected timing of the release of clinical trial data, the plans and objectives of management for future operations and future results of anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,”“anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential”, or “continue” or the negative of these terms or other similar expressions.

The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described under the sections in this Quarterly Report on Form 10-Q titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Board of Directors and Shareholders

Avita Medical, Inc.

Results of review of interim financial statements

We have reviewed the accompanying consolidated balance sheet of Avita Medical, Inc., (a Delaware corporation) and subsidiaries (the “Company”) as of December 31, 2020, and the related consolidated statements of operations, comprehensive loss, shareholders’ equity, and cash flows for the three-month and six-month periods ended December 31, 2020 and 2019, and the related condensed notes (collectively referred to as the “interim financial statements”). Based on our reviews, we are not aware of any material modifications that should be made to the accompanying interim financial statements for them to be in conformity with accounting principles generally accepted in the United States of America.

Basis for review results

These interim financial statements are the responsibility of the Company’s management. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our reviews in accordance with the standards of the PCAOB. A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the PCAOB, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

/s/ GRANT THORNTON LLP

Los Angeles, CA

February 16, 2021

PART I – Financial Information

Item 1. FINANCIAL STATEMENTS

AVITA MEDICAL, INC.

~~AVITA THERAPEUTICS, INC.~~

~~Condensed~~ Consolidated Balance Sheets

(In thousands, except share and per share data)

(Unaudited)


	As of						As of
	September 30, 2020			June 30, 2020			December 31, 2020			June 30, 2020
ASSETS
Cash	$	65,753		$	73,639		$	59,765		$	73,639
Accounts receivable, net		2,360			2,076			1,941			2,076
BARDA receivables		371			356			440			356
Prepaids and other current assets		1,054			990			814			990
Restricted cash		201			201			201			201
Inventory		1,657			1,125			2,289			1,125

Total current assets		71,396			78,387			65,450			78,387
Plant and equipment, net		1,349			1,363			1,488			1,363
Operating lease right-of-use assets		2,216			2,347			1,795			2,347
Intangible assets		403			364
Other long term assets		55			1
Intangible assets, net								420			364
Other long-term assets								152			1

Total assets	$	75,419		$	82,462		$	69,305		$	82,462

LIABILITIES AND SHAREHOLDERS’ EQUITY
Accounts payable and accrued liabilities	$	3,570		$	4,333		$	2,793		$	4,333
Accrued wages and fringe benefits		3,589			2,816			4,305			2,816
Other currrent liabilities		561			560
Other current liabilities								775			560

Total current liabilities		7,720			7,709			7,873			7,709
Contract liabilities		435			435			596			435
Operating lease liabilities, long term		1,776			1,917			1,239			1,917

Total liabilities		9,931			10,061			9,708			10,061

Contingencies (Note 10)
Shareholders’ Equity:
Common stock, $0.0001 par value per share, 200,000,000 shares authorized, 21,623,287 and 21,467,912 shares issued and outstanding at September 30, 2020 and June 30, 2020, respectively		3			3
Preferred stock, $0.0001 par value per share, 10,000,000 shares authorized, no shares issued or outstanding at September 30, 2020 and June 30, 2020		—			—
Common stock, $0.0001 par value per share, 200,000,000 shares authorized, 21,625,058 and 21,467,912 shares issued and outstanding at December 31, 2020 and June 30, 2020, respectively								3			3
Preferred stock, $0.0001 par value per share, 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2020 and June 30, 2020								—			—
Additional paid-in capital		262,431			259,165			262,086			259,165
Accumulated other comprehensive income		8,194			8,146			8,289			8,146
Accumulated deficit		(205,140	)		(194,913	)		(210,781	)		(194,913	)

Total shareholders’ equity		65,488			72,401			59,597			72,401

Total liabilities and shareholders’ equity	$	75,419		$	82,462		$	69,305		$	82,462

The accompanying notes form part of the consolidated financial ~~statements~~statements.

AVITA ~~THERAPEUTICS,~~MEDICAL, INC.

~~Condensed~~ Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)


	Three months ended September 30,						Three months ended December 31,						Six months ended December 31,
	2020			2019			2020			2019			2020			2019
Revenues	$	5,060		$	3,250		$	5,103		$	3,259		$	10,163		$	6,509
Cost of sales		929			619			821			846			1,750			1,465

Gross profit		4,131			2,631			4,282			2,413			8,413			5,044

BARDA income		596			2,051			449			386			1,045			2,437
Operating expenses:
Sales and marketing expenses(1)		2,935			2,962			3,600			3,972			6,865			7,071
General and administrative expenses(1)		5,536			3,071			3,401			7,107			11,703			10,529
Research and development expenses(1)		3,204			1,635			3,361			2,312			6,735			4,131
Share-based compensation		3,266			672

Total operating expenses		14,941			8,340			10,362			13,391			25,303			21,731

Operating loss		(10,214	)		(3,658	)		(5,631	)		(10,592	)		(15,845	)		(14,250	)
Interest expense		7			11			3			9			10			20
Other income		4			103
Other income/(expense)								4			99			8			202

Loss before income taxes		(10,217	)		(3,566	)		(5,630	)		(10,502	)		(15,847	)		(14,068	)
Income tax expense		10			—			11			—			21			—

Net loss	$	(10,227	)	$	(3,566	)	$	(5,641	)	$	(10,502	)	$	(15,868	)	$	(14,068	)

Net loss per common share:
Basic	$	0.48		$	0.19		$	(0.26	)	$	(0.53	)	$	(0.74	)	$	(0.73	)
Diluted	$	0.48		$	0.19		$	(0.26	)	$	(0.53	)	$	(0.74	)	$	(0.73	)

Weighted-average common shares:
Basic		21,503,643			18,719,857			21,623,509			19,877,676			21,563,576			19,298,767
Diluted		21,503,643			18,719,857			21,623,509			19,877,676			21,563,576			19,298,767

(1)	Refer to Note 2 for information about a reclassification of share-based compensation expense

The accompanying notes form part of the unaudited ~~condensed~~ consolidated financial statements.

AVITA ~~THERAPEUTICS,~~MEDICAL, INC.

~~Condensed~~ Consolidated Statements of Comprehensive Loss

(In thousands)

(Unaudited)


	Three months ended September 30,						Three months ended December 31,						Six months ended December 31,
	2020			2019			2020			2019			2020			2019
Net loss	$	(10,227	)	$	(3,566	)	$	(5,641	)	$	(10,502	)	$	(15,868	)	$	(14,068	)
Foreign currency translation gain/(loss)		48			(34	)
Foreign currency translation gain								95			78			143			44

Comprehensive loss	$	(10,179	)	$	(3,600	)	$	(5,546	)	$	(10,424	)	$	(15,725	)	$	(14,024	)

The accompanying notes form part of the unaudited ~~condensed~~ consolidated financial statements.

AVITA ~~THERAPEUTICS,~~MEDICAL, INC.

~~Condensed~~ Consolidated Statements of Shareholders’ Equity

(In thousands, except shares)

(Unaudited)


	Three Months Ended September 30, 2020														Three Months Ended December 31, 2020
	Common Stock														Shares		Amount		Additional Paid-in-Capital			Accumulated Other Comprehensive Income		Accumulated Deficit			Total Shareholders’ Equity
	Shares		Amount		Additional Paid-in- Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit			Total Shareholders’ Equity
Balance at June 30, 2020		21,467,912	$	3	$	259,165	$	8,146	$	(194,913	)	$	72,401
Balance at September 30, 2020																21,623,287	$	3	$	262,431		$	8,194	$	(205,140	)	$	65,488

Net loss		—		—		—		—		(10,227	)		(10,227	)		—		—		—			—		(5,641	)		(5,641	)
Share-based compensation		—		—		3,266		—		—			3,266			—		—		(346	)		—		—			(346	)
Exercise of stock options		3,538		—		—		—		—			—			1,771		—		1			—		—			1
Vesting of restricted stock units		151,837		—		—		—		—			—
Translation gain		—		—		—		48		—			48			—		—		—			95		—			95

Balance at September 30, 2020		21,623,287	$	3	$	262,431	$	8,194	$	(205,140	)	$	65,488
Balance at December 31, 2020																21,625,058	$	3	$	262,086		$	8,289	$	(210,781	)	$	59,597

   Three Months Ended September 30, 2019
   Common Stock
   Shares    Amount    Additional
Paid-in-
Capital    Accumulated
Other
Comprehensive
Income (Loss) Accumulated
Deficit Total
Shareholders’
Equity
Balance at June 30, 2019
   18,712,996    $ 3    $ 165,473    $ 8,184 $ (152,828 ) $ 20,832








Net loss
   —      —      —      —   (3,566 ) (3,566 )
Share-based compensation
   —      —      672    —   —   672
Issuance of common stock to director in lieu of directors fees
   15,853    —      107    —   —   107
Beginning balance adjustment related ot the adoption of ASC 842
   —      —      —      —   (55 ) (55 )
Translation loss
   —      —         (34 ) —   (34 )








Balance at September 30, 2019
   18,728,849    $ 3    $ 166,252    $ 8,150 $ (156,449 ) $ 17,956


	Three Months Ended December 31, 2019
	Shares		Amount		Additional Paid-in-Capital			Accumulated Other Comprehensive Income		Accumulated Deficit			Total Shareholders’ Equity
Balance at September 30, 2019		18,728,849	$	3	$	166,252		$	8,150	$	(156,449	)	$	17,956

Net loss		—		—		—			—		(10,502	)		(10,502	)
Issuance of common stock under direct placement		2,033,898		—		81,702			—		—			81,702
Issuance costs associated with direct placement		—		—		(5,077	)		—		—			(5,077	)
Share-based compensation		—		—		2,903			—		—			2,903
Vesting of restricted stock units		361,111		—		—			—		—			—
Exercise of stock options		50,885		—		248			—		—			248
Translation gain		—		—		—			78		—			78

Balance at December 31, 2019		21,174,743	$	3	$	246,028		$	8,228	$	(166,951	)	$	87,308


	Six Months Ended December 31, 2020
	Shares		Amount		Additional Paid-in-Capital		Accumulated Other Comprehensive Income		Accumulated Deficit			Total Shareholders’ Equity
Balance at June 30, 2020		21,467,912	$	3	$	259,165	$	8,146	$	(194,913	)	$	72,401

Net loss		—		—		—		—		(15,868	)		(15,868	)
Share-based compensation		—		—		2,920		—		—			2,920
Vesting of restricted stock units		151,837		—		—		—		—			—
Exercise of stock options		5,309		—		1		—		—			1
Translation gain		—		—		—		143		—			143

Balance at December 31, 2020		21,625,058	$	3	$	262,086	$	8,289	$	(210,781	)	$	59,597


	Six Months Ended December 31, 2019
	Shares		Amount		Additional Paid-in-Capital			Accumulated Other Comprehensive Income		Accumulated Deficit			Total Shareholders’ Equity
Balance at June 30, 2019		18,712,996	$	3	$	165,473		$	8,184	$	(152,828	)	$	20,832

Net loss		—		—		—			—		(14,068	)		(14,068	)
Issuance of common stock under direct placement		2,033,898		—		81,702			—		—			81,702
Issuance costs associated with direct placement		—		—		(5,077	)		—		—			(5,077	)
Share-based compensation		—		—		3,575			—		—			3,575
Vesting of restricted stock units		361,111		—		—			—		—			—
Exercise of stock options		50,885		—		248			—		—			248
Issuance of common stock to director in lieu of directors’ fees		15,853		—		107			—		—			107
Beginning balance adjustment related to the adoption of ASC 842		—		—		—			—		(55	)		(55	)
Translation gain		—		—		—			44		—			44

Balance at December 31, 2019		21,174,743	$	3	$	246,028		$	8,228	$	(166,951	)	$	87,308

The accompanying notes form part of the unaudited ~~condensed~~ consolidated financial statements.

AVITA ~~Therapeutics,~~Medical, Inc.

~~Condensed~~ Consolidated Statement of Cash Flows

(In thousands)

(Unaudited)


	Three Months ended September 30,						Six Months Ended December 31
	2020			2019			2020			2019
Cash flow from operating activities:
Net loss	$	(10,227	)	$	(3,566	)	$	(15,868	)	$	(14,068	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		211			66			373			164
Non-cash lease expense		131			122			276			247
Loss (gain) on foreign currency transactions		80			(5	)
Remeasurement and foreign currency transaction loss								229			6
Provision (benefit) for doubtful accounts								(6	)		10
Provision for write-down of inventories		(77	)		8			(82	)		19
Share-based compensation		3,266			672			2,920			3,575
Issuance of common stock to directors in lieu of directors fees		—			107
Issuance of common stock to directors in lieu of directors’ fees								—			107
Changes in operating assets and liabilities:
Trade and other receivables		(283	)		(1,915	)		144			(365	)
BARDA receivables		(15	)		309			(84	)		267
Prepaids and other current assets		(65	)		268			177			65
Inventory		(453	)		(135	)		(1,077	)		(164	)
Operating lease liability		(127	)		(132	)		(268	)		(230	)
Other long term assets		(54	)		3
Other long-term assets								(151	)		39
Accounts payable and accrued expenses		(860	)		(810	)		(1,700	)		175
Accrued wages and fringe benefits		765			286			1,474			918
Other current liabilities		(5	)		(155	)		94			(297	)
Other long term liabilities		—			(4	)
Contract liabilities								161			—
Other long-term liabilities								—			(2	)

Net cash used in operations		(7,713	)		(4,881	)		(13,388	)		(9,534	)
Cash flows from investing activities:
Cash paid for property and equipment		(209	)		(86	)
Cash paid for plant and equipment								(472	)		(128	)
Cash paid for patent filing fees		(87	)		(66	)		(163	)		(118	)

Net cash used in investing activities		(296	)		(152	)		(635	)		(246	)
Cash flow from financing activities:
Proceeds from direct placement of common stock								—			81,701
Issuance cost associated with direct placement								—			(5,077	)
Principal repayment of finance lease		(4	)		(17	)		(10	)		(32	)
Proceeds from exercise of stock options								1			248

Net cash used in financing activities		(4	)		(17	)
Net cash provided/(used) in financing activities								(9	)		76,840
Effect of foreign exchange rate on cash and restricted cash		127			(22	)		158			26
Net decrease in cash and restricted cash		(7,886	)		(5,072	)
Net increase (decrease) in cash and restricted cash								(13,874	)		67,086

Cash and restricted cash at beginning of the period		73,840			20,374			73,840			20,374

Cash and restricted cash end of the period	$	65,954		$	15,302		$	59,966		$	87,460

Supplemental Disclosure of Cash Flow Information
Cash paid for income taxes	$	42		$	—		$	42		$	��
Cash paid for Interest	$	1		$	5		$	2		$	10
Fixed assets in accounts payable	$	50		$	—
Plant and equipment purchases not yet paid							$	60		$	51

The accompanying notes form part of the unaudited ~~condensed~~ consolidated financial statements.

AVITA ~~THERAPEUTICS,~~MEDICAL, INC.

Notes to ~~Condensed~~ Consolidated Financial Statements

(Unaudited)

1. The Company

Nature of the Business

The AVITA group of companies (comprising AVITA ~~Therapeutics,~~Medical, Inc. (“AVITA ~~Therapeutics~~” or the “Company”) and its subsidiaries, including AVITA Medical Pty Limited, previously known as AVITA Medical Limited, (“AVITA Medical”)) (collectively, “AVITA Group” or “we”, “us”, or “our”) is a commercial-stage regenerative tissue company focused on the treatment of burns, trauma and other acute injuries, together with skin defects like vitiligo. The Company’s lead product is the RECELL^® System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin^™ Cells using a small sample of the patient’s own skin. In September 2018, the United States Food & Drug Administration (“FDA”) granted premarket approval (“PMA”) to the RECELL System for use in the treatment of acute thermal burns in patients eighteen years and older. Following receipt of our PMA, we commenced commercializing the RECELL System in January 2019 in the United States. In addition, the FDA has granted the Company three Investigational Device Exemptions (“IDEs”) studies which have enabled the Company to initiate pivotal clinical investigational studies to seek expanded FDA (supplementary) PMA of the RECELL System for each of soft tissue reconstruction, pediatric scalds, and vitiligo. Enrollment of those clinical studies is ongoing and, if successful, those studies would enable the Company to commence commercializing the RECELL System in the United States in each of those indications.

Effective December 2, 2020 (United States time), AVITA Therapeutics, Inc., changed its corporate name to AVITA Medical, Inc. after successfully filing a Certificate of Amendment of Certificate of Incorporation with the Secretary of State of the State of Delaware. The Company’s change of name was registered with the Australian Securities and Investments Commission effective as from 6 January 2021. The Company’s common stock continues to trade on The NASDAQ Stock Exchange LLC (“NASDAQ”) under the symbol “RCEL” and its CHESS Depositary Interests (“CDIs”) continue to trade on the Australian Securities Exchange (“ASX”) under the ticker symbol, “AVH”.

In March 2020, the World Health Organization declared the outbreak of a novel strain of the coronavirus (“COVID-19”) a pandemic. COVID-19 is having, and will likely continue to have, an adverse effect on ~~our~~the Company’s business, results of operations, financial condition, and cash flows, and its future impacts remain highly uncertain and unpredictable. The Company has considered the disruptions caused by COVID-19, including lower than forecasted sales, delays to the speed of enrollment in the Company’s clinical trials that may, if successful, support commercial approval and new revenues in additional markets, and macroeconomic factors, that may impact its estimates. The Company has assessed the potential impact of COVID-19 on certain accounting matters including, but not limited to, the allowance for doubtful accounts, inventory reserves and return reserves, as of ~~September 30,~~December 31, 2020 and through the date of this report. During the three months and six months ended ~~September 30,~~December 31, 2020, COVID-19 had minor effects on the Company’s operations and financial position and cash flows. With respect to future operating results, it is not possible at this time to predict, with any degree of precision, the effects of COVID-19. Consequently, actual results for accounting estimates and assumptions, particularly those relating to the recoverability of certain intangible assets and estimates of expected credit losses on accounts receivable could differ from these estimates.

Redomiciliation

On June 29, 2020, the Company, a newly formed Delaware corporation, acquired all of the issued share capital of AVITA Medical, , a then public company incorporated under the laws of the Commonwealth of Australia and former parent company of the AVITA Group. The acquisition was completed pursuant to a scheme of arrangement under Australian law and was approved by the Federal Court of Australia on June 22, 2020, and by shareholders of AVITA Medical on June 15, 2020 (the “Redomiciliation”). Under the Redomiciliation, all of the issued and outstanding ordinary shares of AVITA Medical, including those ordinary shares held in the form of American Depositary Shares (“ADSs”), were exchanged for newly issued shares of common stock of the AVITA ~~Therapeutics~~Medical, Inc. or CHESS Depositary Interests (“CDIs”). This exchange was conducted on the basis of one share of common stock of AVITA ~~Therapeutics~~Medical, Inc. for every 100 ordinary shares of AVITA Medical, effecting an ‘implicit consolidation’ or ‘reverse split’. The holders of ordinary shares of AVITA Medical received one CDI for every 20 ordinary shares held in AVITA Medical, and the holders of AVITA Medical ADSs (each of which previously represented 20 ordinary shares in AVITA Medical) received one share of common stock in AVITA ~~Therapeutics~~Medical, Inc. for every five ADSs held. The common stock of AVITA ~~Therapeutics~~Medical, Inc. began trading on The NASDAQ Stock Exchange LLC (“NASDAQ”) upon market open on July 1, 2020 under the same ticker code, “RCEL” as AVITA Medical’s ADSs were traded under prior to the Redomiciliation.

As part of the exchange of shares under the Redomiciliation, a reverse split was also simultaneously implemented such that the number of shares of common stock on issue in AVITA ~~Therapeutics~~Medical, Inc. (as set out in the ~~condensed~~ consolidated financial statements) is less than the number of ordinary shares in AVITA Medical that was previously set out in the consolidated financial statements of AVITA Medical.

The Redomiciliation resulted in the domicile of the AVITA Group moving from Australia to the United States of America, with AVITA ~~Therapeutics~~Medical, Inc. becoming the ultimate parent company of the AVITA Group. In addition, the existing listing of AVITA Medical ordinary shares on the Australian Securities Exchange (“ASX”) (as its primary listing) and AVITA Medical ADSs on NASDAQ (as its secondary listing) was inverted and replaced with a new listing of AVITA ~~Therapeutics~~Medical, Inc. common stock on NASDAQ (as its primary listing) under the existing ticker symbol, “RCEL” and AVITA ~~Therapeutics~~Medical, Inc. CDIs on the ASX (as its secondary listing) under the existing ticker symbol, AVH. Five CDIs traded on ASX are equivalent to one share of common stock traded on NASDAQ.

As a result of the Redomiciliation, the reporting currency of the AVITA Group has changed from the Australian dollar to the U.S. dollar. In accordance with SEC regulation, S-X Rule 320 (e), the impact of the change in the reporting currency was included in a component of other comprehensive income (loss).

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited ~~condensed~~ consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the fiscal year ended June 30, 2020 filed with the SEC on August 27, 2020 (the “Annual Report”).

There have been no changes to the Company’s significant accounting policies as described in the annual report on Form 10-K that have had a material impact on the Company’s ~~condensed~~ consolidated financial statements. See the summary of the Company’s significant accounting policies set forth in the notes to its consolidated financial statements included in the Annual Report.

Reclassification

Certain amounts in the prior period Consolidated Statement of Operations have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported operating expense, loss before taxes, net loss and earnings per share.

After the issuance of the consolidated financial statements for the year ended June 30, 2020, and the quarter ended September 30, 2020, the Company concluded that the presentation of share-based compensation should be reclassified to the functional expense line items consistent with cash compensation in accordance with SAB Topic 14. The Company has determined that such change in presentation of prior period amounts in the Statement of Operations is not material to the consolidated financial statements.

The Company reclassified share-based compensation expense of $2.9 million for the three months ended December 31, 2019 to sales and marketing expense of $234,000, general and administrative expense of $2.5 million and research and development expenses of $120,000. For the six months ended December 31, 2019, the Company reclassified share-based compensation of $3.6 million to sales and marketing expense of $370,000, general and administrative expense of $2.9 million and research and development expenses of $305,000.

Principles of Consolidation

The accompanying ~~condensed~~ consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. As a result of the Redomiciliation, the parent company of the AVITA Group changed from AVITA Medical to AVITA ~~Therapeutics.~~Medical, Inc. All intercompany transactions and balances have been eliminated on consolidation.

Use of Estimates

The preparation of the accompanying ~~condensed~~ consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts including doubtful accounts, carrying value of long-lived asset, the useful lives of long-lived assets, inventory, accounting for income taxes and share-based compensation and related disclosures. Estimates have been prepared on the basis of the current and available information. However, actual results could differ from estimated amounts.

Foreign Currency Translation and Foreign Currency Transactions

The financial position and results of operations of the Company’s operating non-U.S. subsidiaries are generally determined using the respective local currency as the functional currency of that subsidiary. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each period end. Income statement accounts are translated at the average rate of exchange prevailing during the period. Adjustments arising from the use of differing exchange rates from period to period are included in accumulated other comprehensive gain (loss) in shareholders’ equity. Gains and losses resulting from foreign currency transactions ~~which are not material,~~ are included in general and administrative expenses and were $77,000 and $114,000 for the three and six months ended December 31, 2020, respectively. For the three and six months ended December 31, 2019 amounts were not significant. The Company’s non-operating subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the ~~condensed consolidated statements~~end of ~~operations.~~each period, nonmonetary assets and liabilities at historical rates. Gains and losses resulting from these remeasurements and foreign currency transactions are included in general and administrative expenses and were a gain of $21,000 and a loss of $115,000 for the three and six months ended December 31, 2020, respectively. For the three and six months ended December 31, 2019 amounts were not significant.

Revenue Recognition

Revenues are recognized as control of the product is transferred to customers, at an amount that reflects the consideration expected to be received in exchange for the product. Revenues are recognized net of volume discounts. As such, revenue is recognized only to the extent a significant reversal of revenues is not expected to occur in subsequent periods. Effective July 1, 2018, the Company adopted ASC 606, Revenue from Contracts with Customers, using the modified retrospective method applicable to all contracts that were not completed at the date of initial application. This update outlined a comprehensive new revenue recognition model designed to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ~~The new standard~~ASC 606 also required additional qualitative ~~disclosures. Refer~~disclosures, refer to Note 12 – Revenues for further information.

For the Company’s contracts that have an original duration of one year or less, the Company used the practical expedient applicable to such contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of each reporting period or when the Company expects to recognize this revenue. The Company has further applied the practical expedient to exclude sales tax in the transaction price and expense contract fulfilment costs such as commissions and shipping and handling expenses as incurred.

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, and trade and other receivables. As of ~~September 30,~~December 31, 2020, and June 30, 2020, substantially all of the Company’s cash was deposited in accounts at financial institutions, and amounts exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which its cash is held.

As of ~~September 30,~~December 31, 2020 and June 30, 2020, no single customer accounted for more than 10% of net accounts receivable. For the three months and six months ended ~~September 30,~~December 31, 2020, no single customer accounted for more than 10% of total revenues. For the three months ended ~~September 30,~~December 31, 2019, no single customer accounted for more than 10% of total revenues. For the six months ended December 31, 2019, one customer accounted for ~~13%~~approximately 11% of total revenues.

Restricted Cash

Pursuant to a contractual agreement with American Express to maintain the business credit card, the Company must maintain restricted cash deposits which amounted to approximately $201,000 and $201,000 as of December 31, 2020 and June 30, 2020, respectively.

BARDA Income and Receivables

The AVITA Group was awarded a Biomedical Advance Research and Development Authority (“BARDA”) contract in September 2015. Under this arrangement BARDA ~~supports~~supported the Company’s research and development for the Company’s product, including the ongoing U.S. clinical regulatory program targeted towards PMA, our compassionate use program, clinical and health economics ~~research, and U.S. pediatric burn programs.~~research. The BARDA contract supports the Company’s ongoing Pediatric Scalds clinical trial.

Consideration received under the BARDA arrangement is earned and recognized under a cost-plus-fixed-fee arrangement in which the Company is reimbursed for direct costs incurred plus allowable indirect costs and a fixed-fee earned. Billings under the contracts are based on approved provisional indirect billing rates, which permit recovery of fringe benefits, general and administrative expenses and a fixed fee.

The Company has concluded that grants under the BARDA relationship is not within the scope of ASC 606, as it does not meet the definition of a contract with a “customer.” The Company has further concluded that Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition also does not apply, as the Company is a business entity and the payments are with governmental agencies or units. With respect to the BARDA arrangement, we considered the guidance in IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, by analogy. BARDA income and related receivables are recognized when there is reasonable assurance that the amount will be received, and all attaching conditions have been complied with. When the payment relates to an expense item, the amount received is recognized as income over the period when the expense was incurred.

3. Accounting Standards Update

~~Recently Adopted Accounting Pronouncements~~

~~In August 2018, the FASB issued ASU~~ ~~No. 2018-15,~~~~Intangibles-Goodwill and~~ ~~Other-Internal-Use~~ ~~Software~~ ~~(Subtopic~~ ~~350-40):~~ ~~Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which provides new guidance on the accounting for implementation,~~ ~~set-up,~~ ~~and other upfront costs incurred in a hosted cloud computing arrangement. Under the new guidance, entities will apply the same criteria for capitalizing implementation costs as they would for an~~ ~~internal-use~~ software license arrangement. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This ASU can be adopted prospectively to eligible costs incurred on or after the date of adoption or retrospectively. Effective July 1, 2020, the Company adopted this standard using the prospective transition method. The adoption of this update did not have a material impact on the Company’s condensed consolidated financial statements.

Recent Accounting Pronouncements Not Yet Adopted

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes, or ASU 2019-12, which includes amendments to simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC 740, Income Taxes, or ASC 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC 740 by clarifying and amending existing guidance. The new guidance is effective for the Company for annual periods beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption of the amendments is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2019-12 will have on its ~~condensed~~ consolidated financial statements.

4. Leases

On July 1, 2019, the Company adopted Accounting Standards Codification No. 842, Leases, (“ASC 842”), which requires lessees to recognize operating leases on the balance sheet as a right-of-use asset (“ROU”) and lease liability.

At contract inception, the Company determines whether the contract is a lease or contains a lease. A contract contains a lease if the Company is both able to identify an asset and can conclude it has the right to control the identified asset for a period of time. Leases with an initial term of twelve months or less are not recorded on the ~~condensed~~ consolidated balance sheet.

The Company has operating leases for corporate office space, manufacturing and warehouse facility. The Company has finance leases for equipment and furniture. The Company’s leases have remaining lease terms of less than one year to five years, some of which include options to renew the lease. Approximately ~~$7,000~~$2,000 and $11,000 in finance leases was included in Other current liabilities as of ~~September 30,~~December 31, 2020 and June 30, 2020, respectively.

During November 2020, the Company remeasured the lease liability for an office lease due to a change in the lease term. As a result of the remeasurement of the lease liability, there was a reduction of approximately $563,000 to the operating lease ROU assets and operating lease liabilities. There was no impact on earnings as a result of the modification. In addition to the modification for the office lease, the Company entered into a new lease in November 2020 for additional warehouse space. The new lease resulted in an increase of $236,000 to the operating lease ROU assets and operating lease liabilities.

ROU assets represent the Company’s right to control an underlying asset for the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate (“IBR”) based on the information available at commencement date or modification date in determining the discount rate used to present value lease payments. The Company used the IBR on July 1, 2019 for its operating leases that commenced on or prior to that date. For leases that were modified and entered into in the current period, the Company used the IBR in effect on the commencement date or modification date. In determining the IBR, the Company considered its credit rating and current market interest rates. The IBR used approximates the interest that the Company would be required to pay for a collateralized loan over a similar term. Additionally, the Company used the portfolio approach when applying the discount rate selected based on the dollar amount and term of the obligation. Certain leases for equipment and furniture contain bargain purchase options and are classified as finance leases. The Company’s leases typically do not include any residual value guarantees or asset retirement obligations.

The Company’s lease terms are only for periods in which it has enforceable rights. A lease is no longer enforceable when both the lessee and the lessor each have the right to terminate the lease without permission from the other party with no more than an insignificant penalty. The Company has options to renew some of these leases for three years after their expiration. The Company considers these options, which may be elected at the Company’s sole discretion, in determining the lease term on a lease-by-lease basis.

Some leases require variable payments for common area maintenance, property taxes, parking, insurance, and other variable costs. The variable portion of lease payments is not included in operating lease ROU assets or operating lease liabilities. Variable lease costs are expensed when incurred.

The following table sets forth the Company’s operating lease expense which are included in general and administrative expenses in the consolidated statements of operations (in thousands):

   Three Months ended
September 30, 2020    Three Months ended
September 30, 2019
Operating lease cost
   $ 175    $ 175
Variable lease cost
   12    12




Total lease cost
   $ 187    $ 187


	Three Months ended December 31,				Six Months ended December 31,
	2020		2019		2020		2019
Operating lease cost	$	184	$	360	$	175	$	351
Variable lease cost		12		24		12		23

Total lease cost	$	196	$	384	$	187	$	374

Supplemental cash flow information related to operating leases for the ~~three~~six months ended ~~September 30,~~December 31, 2020 and 2019 was as follows (in thousands):


	Three Months ended September 30, 2020		Three Months ended September 30, 2019			Six Months ended December 31, 2020		Six Months ended December 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:					Cash paid for amounts included in the measurement of lease liabilities:
Operating cash outflows from operating leases	$	171	$	166		$	352	$	334

Supplemental balance sheet information, as of ~~September 30,~~December 31, 2020 and June 30, 2020 related to operating leases was as follows (in thousands):


	As of September 30, 2020			As of June 30, 2020			As of December 31, 2020			As of June 30, 2020
Reported as:
Operating lease right-of-use assets	$	2,216		$	2,347		$	1,795		$	2,347

Total right-of-use assets	$	2,216		$	2,347		$	1,795		$	2,347

Other current liabilities:
Operating lease liabilities, short-term	$	548		$	533		$	667		$	533
Operating lease liabiltiies, long term		1,776			1,917
Operating lease liabilities, long term								1,239			1,917

Total operating lease liabilities	$	2,324		$	2,450		$	1,906		$	2,450

Operating lease weighted average remaining lease term (years)		3.66			3.91			3.05			3.91
Operating lease weighted average discount rate		7.50	%		7.50	%		6.62	%		7.50	%

As of ~~September 30,~~December 31, 2020, maturities of the Company’s operating lease liabilities are as follows (in thousands):


	Operating Leases			Operating Leases
Remaining 2021	$	524		$	383
2022		717			784
2023		740			428
2024		588			413
2025 and thereafter		87			105

Total lease payments	$	2,656		$	2,113
Less imputed interest		(332	)		(207	)

Total operating lease liabilities	$	2,324		$	1,906

As of ~~September 30,~~December 31, 2020, there were no leases entered into that had not yet commenced.

5. Inventory

The composition of ~~inventories~~inventory is as follows (in thousands):


	September 30, 2020		June 30, 2020		December 31, 2020		June 30, 2020
Raw materials	$	1,035	$	947	$	1,139	$	947
Work in process inventory		271		—		653		—
Finished goods		351	$	178		497		178

Total inventory	$	1,657	$	1,125	$	2,289	$	1,125

The Company has reduced the carrying value of its inventories to reflect the net realizable value. Charges for estimated excess and obsolescence are recorded in cost of sales in the ~~condensed~~ consolidated ~~statement~~statements of operations. Inventory impairments recognized in cost of sales are a result of expired product and were ~~$43,000~~$12,000 and ~~$53,000~~$55,000 for the three months and six months ended ~~September 30,~~December 31, 2020, respectively and $134,000 and $187,000 for the three and six months ended December 31, 2019, respectively.

6. Intangible Assets

The composition of intangible assets, net is as follows (in thousands):


			As of September 30, 2020							As of June 30, 2020									As of December 31, 2020							As of June 30, 2020
	Weighted Average Life		Gross Amount		Accumulated Amortization			Net Carry Amount		Gross Amount		Accumulated Amortization			Net Carry Amount		Weighted Average Life		Gross Amount		Accumulated Amortization			Net Carry Amount		Gross Amount		Accumulated Amortization			Net Carry Amount
Patent 1		3	$	237	$	(121	)	$	116	$	235	$	(101	)	$	134		3	$	258	$	(142	)	$	116	$	235	$	(101	)	$	134
Patent 2		14		105		(9	)		96		74		(9	)		65		14		106		(11	)		95		74		(9	)		65
Patent 3		15		127		(11	)		116		125		(9	)		116		15		141		(13	)		128		125		(9	)		116
Patent 5		20		46		(1	)		45		26		—			26		20		46		(2	)		44		26		—			26
Trademarks		Indefinite		30		—			30		23		—			23		Indefinite		37		—			37		23		—			23

Total intangible assets			$	545	$	(142	)	$	403	$	483	$	(119	)	$	364			$	588	$	(168	)	$	420	$	483	$	(119	)	$	364

During the three and six months ended ~~September 30,~~December 31, 2020 and 2019, the Company did not identify any events or changes in circumstances that indicated the carrying value of its intangibles may not be recoverable. As such, there was no impairment of intangibles assets recognized for the three and six months ended ~~September 30,~~December 31, 2020 and 2019. Amortization expense of intangibles included in the ~~condensed~~ consolidated statements of operations was ~~$23,000~~$26,000 and $0$49,000 for the three and six months ended ~~September 30,~~December 31, 2020, respectively and $0 and $10,000 for the three and six months ended December 31, 2019, respectively.

The Company expects the future amortization of amortizable intangible assets held at ~~September 30,~~December 31, 2020 to be (in thousands):


	Estimated Amortization Expense		Estimated Amortization Expense
Remainder of 2021	$	70	$	55
2022		67		79
2023		21		22
2024		21		22
2025		21		22
2026 and thereafter		173		183

Total	$	373	$	383

7. ~~Property,~~ Plant and Equipment

The composition of property, plant and equipment, net is as follows (in thousands):


	Useful Lives	As of September 30, 2020			As of June 30, 2020			Useful Lives		As of December 31, 2020			As of June 30, 2020
Computer equipment	3 years	$	825		$	802			3 years	$	849		$	802
Computer software	3 years		496			369			3 years		514			369
Construction in progress			91			138					276			138
Furniture and fixtures	7 years		427			425			7 years		427			425
Laboratory equipment	5 years		233			194			5 years		255			194
Leasehold improvements	Lesser of life or lease term		216			216			Lesser of life or lease term		242			216
RECELL Moulds	5 years		130			100			5 years		130			100
Less: accumulated amortization and depreciation			(1,069	)		(881	)				(1,205	)		(881	)

Total property, plant and equipment, net		$	1,349		$	1,363				$	1,488		$	1,363

Depreciation expense related to plant and equipment ~~was $188,000 and $66,000~~ for the three months ended ~~September 30,~~December 31, 2020 and 2019 was $135,000 and $88,000, respectively. Depreciation expense for the six months ended December 31, 2020 and 2019, was $324,000 and $154,000 respectively.

8. Prepaids and Other Current Assets

Prepaids and other current assets consisted of the following (in thousands):


	As of September 30, 2020		As of June 30, 2020		As of December 31, 2020		As of June 30, 2020
Prepaid expenses	$	850	$	792	$	637	$	792
Lease deposits		98		123		2		123
Other receivables		106		75		50		75
Contract assets						125		0

Total prepaids and other current assets	$	1,054	$	990	$	814	$	990

Prepaid expenses primarily consist of prepaid benefits and insurance. For information regarding contract assets refer to Note 12.

9. Reporting Segment and Geographic Information

The Company views its operations and manages its business in one reporting segment. Long-lived assets were primarily located in the United States as of ~~September 30,~~December 31, 2020 and June 30, 2020 with an insignificant amount located in Australia and the United Kingdom. Revenue by region for the three and six months ended ~~September 30,~~December 31, 2020 and 2019 were as follows (in thousands):


					Three Months Ended December 31,				Six Months Ended December 31,
	Three Months ended September 30, 2020		Three Months ended September 30, 2019		2020		2019		2020		2019
Revenue:
United States	$	4,970	$	3,130	$	5,020	$	3,099	$	9,990	$	6,229
Foreign:
Australia		80		46		53		125		133		171
United Kingdom		10		74		30		35		40		109

Total	$	5,060	$	3,250	$	5,103	$	3,259	$	10,163	$	6,509

10. Contingencies

The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, the lowest amount in the range is accrued. The Company expenses legal costs associated with loss contingencies as incurred. As of ~~September 30,~~December 31, 2020 and June 30, 2020, the Company did not have any outstanding or threatened litigation that would have a material impact to the financial statements.

11. Common and Preferred Stock

On June 29, 2020, a statutory scheme of arrangement under Australian law to effect a redomiciliation of the AVITA Group from Australia to the United States of America was implemented (the “Scheme”). The Scheme was approved by shareholders on June 15, 2020 and approved by the Federal Court of Australia on June 22, 2020.

Pursuant to the Scheme, all ordinary shares in AVITA Medical, the former parent company of the AVITA Group, were exchanged for shares of common stock in AVITA ~~Therapeutics.~~Medical, Inc., which at the time was named AVITA Therapeutics, Inc. As a result, AVITA ~~Therapeutics~~Medical, Inc. became the sole shareholder of AVITA Medical and the new parent company of the AVITA Group. In conjunction with the Scheme, an implicit reverse split on a 1 for 100 basis was implemented whereby shareholders of AVITA Medical received one share of common stock in AVITA ~~Therapeutics~~Medical, Inc. for every 100 ordinary shares held in AVITA Medical. AVITA Therapeutics, Inc. changed its name to AVITA Medical, Inc. in December 2020.

Under the Scheme, eligible shareholders in AVITA Medical received consideration in the form of:

five CDIs in AVITA ~~Therapeutics~~Medical, Inc. for every 100 ordinary shares in AVITA Medical that were held by them; or

one share of common stock in AVITA ~~Therapeutics~~Medical, Inc. for every 5 ADSs in AVITA Medical that were held by them.

The Company’s CDIs are quoted on the ASX under AVITA Medical’s existing ASX ticker code, “AVH”. The Company’s shares of common stock are quoted on NASDAQ under AVITA Medical’s existing NASDAQ ticker code, “RCEL”. One share of common stock on NASDAQ is equivalent to five CDIs on the ASX.

As a result of the ‘implicit consolidation’ that occurred under the Scheme, the number of shares of common stock on issue in the Company (as set out in the ~~condensed~~ consolidated financial statements) is less than the number of ordinary shares in AVITA Medical that was previously set out in the consolidated financial statements of AVITA Medical. All common share amounts included in the ~~condensed~~ consolidated financial statements have been retroactively reduced by a factor of one hundred and all per share amounts have been increased by a factor or one hundred, with the exception of the Company’s common stock par value.

The Company is authorized to issue 200,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, issuable in one or more series as designated by the Company’s board of directors. No other class of capital stock is authorized. As of ~~September 30,~~December 31, 2020, and June 30, 2020, ~~21,623,287~~21,625,058 and 21,467,912 shares of common stock, respectively, were issued and outstanding and no shares of preferred stock were outstanding.

12. Revenues

Revenues

The Company’s revenue consists of sale of the RECELL System to hospitals or other treatment centers (“customers”), predominately in the United States.

Contract Assets and Contract Liabilities

The Company receives payments from customers based on contractual terms. Trade receivables are recorded when the right to consideration becomes unconditional. The Company satisfies its performance obligation on product sales when the products are shipped or delivered, depending on the terms of the sale. Payment terms on invoiced amounts are typically 30-90 days, and do not include a financing component.

Contract assets include amounts related to the Company’s contractual right to consideration for both completed and partially completed performance for which the Company does not have the right to payment. As of ~~September 30,~~December 31, 2020, and June 30, 2020, the Company ~~did not have any~~had $125,000 and $0 in contract ~~assets.~~assets, respectively.

Contract liabilities are recorded when the Company receives payment prior to satisfying its obligation to transfer goods to a customer. The Company had ~~$435,000~~$596,000 and $435,000 of contract liabilities as of ~~September 30,~~December 31, 2020 and June 30, 2020, respectively. For the three months ended ~~September 30,~~December 31, 2020 and 2019, revenue recognized from amounts included in the beginning balance of contract liabilities was not significant.

Remaining Performance Obligations

Revenues from remaining performance obligations are calculated as the dollar value of the remaining performance obligations on executed contracts. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) pursuant to the Company’s existing customer agreements is $9.6 million as of ~~September 30,~~December 31, 2020. The majority of which relates to our July 13, 2020 contract with BARDA for the purchase, delivery and storage of RECELL Systems under the Strategic National Stockpile (“SNS”) for a period of three years for use in a mass casualty or other emergency situation.

13. Share-Based Payment Plans

Overview of Employee Share-Based Compensation Plans

In November 2014, our former parent company, AVITA Medical, adopted the Employee Share Plan and the Incentive Option Plan (collectively, the “2016 Plans”). The 2016 Plans previously authorized the issuance of stock options or other share-based instruments representing up to 7.5% of outstanding capital of AVITA Medical. Any increase in the maximum number of shares issuable under the 2016 Plans was subject to shareholder approval or to an increase in the total number of ordinary shares outstanding. Upon Redomiciliation, the 2016 Plans were terminated with respect to future grants and accordingly, there are no more shares available to be issued under the 2016 Plans. In addition, upon Redomiciliation, the Company had an implicit 100-1 reverse stock split and all share information presented below has been presented on a reverse split stock basis. ~~At the 2020 Annual Meeting of Stockholders that will be held on~~

During November 9, 2020, the Company, ~~intends~~pursuant to ~~seek shareholder approval for~~Rule 416 under the Securities Act of 1933, filed a ~~new employee~~registration statement on form S-8 to register a total of 1,750,000 shares of common stock ~~option plan.~~which may be issued pursuant to the terms of the Avita Medical, Inc. 2020 Omnibus Incentive Plan.

Share-Based Payment Expenses

Share-based payment transactions are recognized as compensation cost based on the fair value of the instrument on the date of grant. ~~The~~For shares granted under the 2020 Omnibus Incentive Plan, the Company uses the ~~binomial~~Black Scholes option valuation model to estimate the grant date fair value of employee stock options. For the shares granted under the 2016 Plan the Company used the Binomial valuation model to estimate the grant date fair value of the stock options.

During the three months ended ~~September 30,~~December 31, 2020 the Company recorded a net reduction of $346,000 to share-based compensation expense. For the six months ended December 31, 2020, the Company recorded $2.9 million in compensation expense. For the three and six months ended December 31, 2019, the Company recorded ~~stock-based compensation expense of $3.2~~$2.9 million and ~~$672,000,~~$3.5 million, respectively. No income tax benefit was recognized in the ~~condensed~~ consolidated ~~statement~~statements of comprehensive loss for share-based payment arrangements for the three and six months ended ~~September 30,~~December 31, 2020 and 2019.

The Company has included share-based compensation expense as part of operating expenses in the accompanying Consolidated Statements of Operations as follows:


	Three Months Ended December 31,					Six Months Ended December 31,
	2020			2019		2020		2019
Sales and marketing expenses		294			234		624		370
General and administrative expenses		(774	)		2,549		1,992		2,900
Research and development expenses		134			120		304		305

Total		(346	)		2,903		2,920		3,575

A summary of stock option activity under the employees share option plan arrangement as of ~~September 30,~~December 31, 2020 and changes during the period then ended is presented below:


	Service Only Stock Options			Performance Based Stock Options			��	Total Stock Options			Service Only Stock Options			Performance Based Stock Options			Total Stock Options
Outstanding at June 30, 2020		904,353			356,171				1,260,524			904,353			356,171			1,260,524
Exercised		(3,538	)		—				(3,538	)		(5,309	)		—			(5,309	)
Expired		(1,636	)		(2	)			(1,638	)		(3,565	)		(2	)		(3,567	)
Forfeited		(21,778	)		—				(21,778	)		(74,878	)		(22,500	)		(97,378	)

Outstanding at September 30, 2020		877,401			356,169				1,233,570
Outstanding at December 31, 2020												820,601			333,669			1,154,270

Exercisable at September 30, 2020		296,803			298,897				595,700
Exercisable at December 31, 2020												384,256			298,897			683,153

Restricted Stock Units

Restricted stock units (“RSUs”) are granted to executives as part of their long-term incentive compensation. RSU awards are approved by the Compensation Committee as determined necessary. The RSU awards have a contractual term of 10 years and vest in accordance with the tenure or performance conditions as determined by the Compensation Committee. The grant date fair value is determined based on the price of the Company stock on the ASX on the date of grant. RSUs primarily consist of awards to the Chief Executive Officer and other executives.

A summary of the ~~status of the~~ Company’s unvested shares activity as of ~~September 30, 2020,~~ and ~~changes during~~for the ~~three~~six months ended ~~September 30,~~December 31, 2020, is presented below:


	Service Condition RSU		Performance Condition RSUs			Total RSU			Service Condition RSU		Performance Conditions RSU			Total RSU
Unvested RSUs outstanding at June 30, 2020		95,013		244,346			339,359			95,013		244,346			339,359
Granted										—		5,000			5,000
Vested		—		(151,837	)		(151,837	)		—		(151,837	)		(151,837	)
Forfeited		—		(2	)		(2	)		—		(45,002	)		(45,002	)

Unvested RSUs outstanding at September 30, 2020		95,013		92,507			187,520
Unvested RSUs outstanding at December 31, 2020										95,013		52,507			147,520

14. Income Taxes

At June 30, 2020, the Company and its subsidiaries had net operating loss carryforwards for U.S. federal, state, United Kingdom, and Australian income tax purposes of $88.5 million, $57.5 million, $29.8 million, and $34.1 million, respectively. The net operating loss carryforwards may be subject to limitation regarding their utilization against taxable income in future periods due to “change of ownership” provisions of the Internal Revenue Code and similar state and foreign provisions. Of these carryforwards, $21.7 million will expire, if not utilized, in various years through 2038. The remaining loss carryforwards have no expiration.

In assessing the recoverability of its deferred tax assets, the Company considers whether it is more likely than not that its deferred assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible and/or net operating losses can be utilized. The Company considers all positive and negative evidence when determining the amount of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, historical earnings, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income. Based upon the weight of available evidence including the uncertainty regarding the Company’s ability to utilize certain net operating losses and tax credits in the future, the Company has established a full valuation allowance against all its net deferred tax assets. The deferred tax assets are primarily net operating loss carryforwards for which management has determined it is more likely than not that the deferred tax assets will not be realized.

The Company recognizes the tax benefit from an uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the ~~condensed~~ consolidated financial statements related to a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement. The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.

The Company has not identified any uncertain tax positions as of ~~September 30,~~December 31, 2020 or June 30, 2020.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”Act”) was enacted in the United States. The CARES Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding the prior and future utilization of net operating losses and technical corrections from prior tax legislation for tax depreciation of certain qualified improvement property. The Company evaluated the provisions of the CARES Act and does not anticipate the associated impacts, if any, will have a material effect on its financial position.

15. Net Loss per Share

The following is a reconciliation of the basic and diluted loss per share computations:


	Three Months Ended September 30,				Three months ended December 31,				Six months ended December 31,
	2020		2019		(in thousands, except per share data)
	(in thousands, expect per share data)				2020		2019		2020		2019
Net Loss	$	10,227	$	3,566	$	5,641	$	10,502	$	15,868	$	14,068
Weighted-average common shares - outstanding, basic		21,504		18,720		21,624		19,878		21,564		19,299
Weighted-average common shares - outstanding, diluted		21,504		18,720		21,624		19,878		21,564		19,299

Net loss per common share, basic	$	0.48	$	0.19	$	0.26	$	0.53	$	0.74	$	0.73

Net loss per common share, diluted	$	0.48	$	0.19	$	0.26	$	0.53	$	0.74	$	0.73

The Company’s basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the relevant period. For the purposes of the calculation of diluted net loss per share options to purchase common stock, restricted stock units and unvested shares of common stock issued upon the early exercise of stock options have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive. Because the Company has reported a net loss for the three and six months ended ~~September 30,~~December 31, 2020 and 2019, diluted net loss per common share is the same as the basic net loss per share for those periods.

The loss per share incorporates the impact of the reverse stock split that was effectuated in conjunction with the Redomicilation. In accordance with ASC 260, the impact of the reverse stock split was retrospectively applied for all periods presented.

16. Retirement Plans

The Company offers a 401(k)-retirement savings plan (the ~~“401(k)~~“401(k) Plan”) for its employees, including its executive officers, who satisfy certain eligibility requirements. The Internal Revenue Code of 1986, as amended, allows eligible employees to defer a portion of their compensation, within prescribed limits, on a pre-tax basis through contributions to the 401(k) Plan. The Company matches contributions to the 401(k) Plan based on the amount of salary deferral contributions the participant makes to the 401(k) Plan. The Company will match up to 6% of an employee’s compensation that the employee contributes to his or her 401(k) Plan account. Total Company matching contributions to the 401(k) Plan were ~~$165,000~~$145,000 and ~~$154,000~~$138,000 in the three months ended ~~September 30,~~December 31, 2020 and 2019, respectively and $310,000 and $293,000 for the six months ended December 31, 2020 and 2019, respectively.

17. Subsequent Events

The Company has ~~considered all~~evaluated subsequent events ~~occurring subsequent to September 30, 2020~~through the filing of this Quarterly Report on Form 10-Q and ~~has concluded~~determined that ~~all significant events~~there have been ~~disclosed~~no events that have occurred that would require adjustments to our disclosures in the ~~condensed~~ consolidated financial ~~statements and accompanying notes.~~statements.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited ~~condensed~~ consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q.

Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report on Form 10-Q, they may not be predictive of results or developments in future periods.

The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Quarterly Report on Form 10-Q, including those risks identified under Part II, Item 1A. Risk Factors.

We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Overview

The AVITA group of companies (comprising AVITA ~~Therapeutics,~~Medical, Inc. (“AVITA ~~Therapeutics~~” or the “Company”) and its subsidiaries, including AVITA Medical Pty Limited (“AVITA Medical”)) (collectively, “AVITA Group” or “we”, “us”, or “our”) is a regenerative medicine group with a technology platform positioned to address unmet medical needs in burn injuries, trauma and other acute injuries, together with skin defects like vitiligo. Our patented and proprietary platform technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. Our medical device works by preparing Spray-On Skin^™ Cells, an autologous cellular suspension comprised of the patient’s skin cells, which is then sprayed on the patient in order to regenerate natural healthy epidermis.

Our first United States (“U.S.”) product, the RECELL^® System, was approved by the U.S. Food and Drug Administration (“FDA”) in September 2018 for the treatment of acute thermal burn injuries in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, and simultaneously significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care as a standalone product, or in combination with “skin transplants”, known as split-thickness skin autografts, depending on the depth of the burn injury. The pivotal studies leading to the RECELL System’s FDA premarket approval (“PMA”) for the treatment of acute thermal burns, demonstrated that the RECELL System treated burns using 97.5 percent less donor skin when used alone in second-degree burns, and 32 percent less donor skin when used with autograft for third-degree burns compared to standard of care autografting.

In these studies, a statistically significant reduction in donor skin required to treat burn patients with the RECELL System was realized without any associated compromise to healing or safety outcomes. Donor site outcomes from the clinical trial for second-degree burns also revealed a statistically significant reduction in patient-reported pain, increased patient satisfaction and improved scar outcomes.

Our compelling data from prospective, randomized, controlled clinical trials conducted at major United States burn centers, health economics modeling, and real-world use globally, demonstrate that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings.

Following receipt of our PMA, we commenced commercializing the RECELL System in January 2019 in the U.S., and we expect the dominant focus of our commercial efforts to be directed towards the U.S. market going forward.

The RECELL System is Therapeutic Goods Administration (“TGA”)~~-registered~~ registered in Australia cleared for use in the treatment of burns, acute wounds, scars and repigmentation (vitiligo). In Europe, the RECELL System received CE-mark approval for the treatment of burns, chronic wounds, scars and vitiligo. Presently, we are not actively marketing the RECELL System internationally and therefore do not derive meaningful revenue from the RECELL System in these markets.

Our website address is www.avitamedical.com. Information contained on our website is not part of or incorporated into this report. We make our periodic reports, together with any amendments, available on our website, free of charge, as soon as reasonably

practicable after we electronically file or furnish the reports with the Securities and Exchange Commission (“SEC”) or with the Australian Securities Exchange (“ASX”). The SEC maintains an internet site, www.sec.gov, which contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Copies of announcements made by the Company to the ASX are available on ASX’s website (www.asx.com.au).

Corporate History

AVITA Therapeutics, Inc. (now AVITA Medical, Inc), a Delaware corporation, was originally formed in April 2020. The former parent company of the AVITA Group, AVITA Medical Pty Limited (“AVITA Medical”) was formed under the laws of the Commonwealth of Australia in December of 1992 and has operated as AVITA Medical since 2008. AVITA Medical’s ordinary shares originally began trading in Australia on the ASX on August 9, 1993. AVITA Medical’s ordinary shares, in the form of American Depositary Shares (“ADSs”), began trading on the NASDAQ Stock Market LLC (“NASDAQ”) on October 1, 2019 under the ticker symbol “RCEL”.

~~With effect from~~On June 29, 2020, a statutory scheme of arrangement was implemented under Australian law to change the domicile of the AVITA Group from Australia to the U.S. Under the scheme of arrangement, AVITA Therapeutics ~~being a company incorporated in the State of Delaware in the U.S.,~~ became the new parent company of the AVITA Group, and all ordinary shares in AVITA Medical (including ordinary shares represented by ADSs) held by securityholders were exchanged for shares of common stock or CHESS Depositary Interests (“CDIs”). As a result, the existing listing of AVITA Medical Ltd. on the ASX (as its primary listing) and on NASDAQ (as its secondary listing) was inverted and replaced with a new listing of AVITA Therapeutics on NASDAQ (as its primary listing) under the existing ticker symbol, “RCEL”, and on the ASX (as its secondary listing) under the existing ticker symbol, “AVH”. AVITA Therapeutics’ shares of common stock trade on NASDAQ and its CDIs trade on ASX (with five CDIs trading on ASX representing one share of common stock on NASDAQ).On December 2, 2020, AVITA Therapeutics, Inc., changed its corporate name to AVITA Medical, Inc. after filing a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware. The Company’s change of name was registered with the Australian Securities and Investments Commission effective as from 6 January 2021. The Company’s common stock continues to trade on NASDAQ under the symbol “RCEL” and the Company’s CDIs continue to trade on the ASX under the ticker symbol “AVH”.

COVID-19 Business Update and Risks Associated with COVID-19

The global COVID-19 pandemic presents significant risks to us and may have far reaching impacts on our business, operations, and financial results and condition, directly and indirectly, including, without limitation, impacts on: the health of our management and employees; manufacturing, distribution, marketing and sales operations; research and development activities, including clinical activities; and customer and patient behaviors.

Beginning in March 2020, the COVID-19 pandemic began impacting our operations and financial results. For example, on March 19, 2020, the Executive Department of the State of California issued Executive Order N-33-20, ordering all individuals in the State of California to stay at home or at their place of residence except as needed to maintain continuity of operations of federal critical infrastructure sectors. Our primary operations are located in Santa Clarita and Ventura, California. We have taken a variety of steps to address the impact of the COVID-19 pandemic, while attempting to minimize business disruption. Essential staff in manufacturing and limited support functions have continued to work from our locations following appropriate hygiene and social distancing protocols.

To reduce the risk to our employees and their families from potential exposure to COVID-19, all other staff have been required to work from home (excluding our field force). We have restricted non-essential travel to protect the health and safety of our employees and customers.

Moreover, beginning in March 2020, access to hospitals and other customer sites was restricted to essential personnel, which has negatively impacted our ability to promote the use of the RECELL System with physicians, and to enroll our clinical studies. In addition, some hospitals and other burn centers suspended the treatment of burn patients or re-distributed those patients to other treatment facilities and, together with a general reduction in broader economic activity (e.g., reduced travel, reduced mobility, suspension of certain business operations, etc.), this resulted in a ~~significant~~ reduction in the volume of burn procedures using the RECELL System in the immediate period following the implementation of those protective measures. In addition, more recently we have experienced periodic enrollment cessation due to COVID-19 as well as having individuals excluded because they have contracted COVID-19.

Approximately 50% of the Company’s revenues come from twenty accounts with physicians and hospitals. These accounts as well are susceptible to the effects of COVID-19 and COVID-19 restrictions. To the extent that COVID-19 or other factors cause such physicians or hospitals to be unable to treat patients or delay the treatment of patients using the RECELL System in a particular quarter, or make patients unavailable because of COVID-19, our revenues could be negatively effected.

We are continuing to monitor the impact of the COVID-19 pandemic on our employees and customers and on the markets in which we operate and will take further actions that we consider prudent to address the COVID-19 pandemic, including reducing spending, while ensuring that we can support our customers and continue to develop our products. The ultimate extent of the impact of the COVID-19 pandemic on us remains highly uncertain and will depend on future developments and factors that continue to ~~evolve, most~~evolve. These factors, among others include the widespread vaccination of populations, especially in the U.S. and improvements in treatments and therapeutics for those with COVID-19, which are outside of our control, and could exist for an extended period of time even after the pandemic might end. Quarantines, shelter-in-place and similar government orders have also impacted and may continue to impact, our third-party manufacturers and suppliers, and could in turn adversely impact the availability or cost of materials, which could disrupt our supply chain.

Results of Operations for the three months ended December 31, 2020 compared to the three months ended December 31, 2019.

The table below summarizes the results of our continuing operations for each of the periods ~~presented.~~presented (in thousands).

   Three months ended
September 30,
   2020    2019    $ Change    % Change
Revenues
   $ 5,060    $ 3,250    $ 1,810    56 %
Cost of sales
   929    619    310    50 %








Gross profit
   4,131    2,631    1,500    57 %








BARDA income
   596    2,051    (1,455 )    -71 %
Operating expenses:

Sales and marketing expenses
   2,935    2,962    (27 )    -1 %
General and administrative expenses
   5,536    3,071    2,465    80 %
Research and development expenses
   3,204    1,635    1,569    96 %
Share-based compensation
   3,266    672    2,594    386 %








Total operating expenses
   14,941    8,340    6,601    79 %








Operating loss
   (10,214 )    (3,658 )    (6,556 )    179 %
Interest expense
   7    11    (4 )    -36 %
Other income
   4    103    (99 )    -96 %








Loss before income taxes
   (10,217 )    (3,566 )    (6,651 )    187 %
Income tax expense
   10    —      10    100 %








Net loss
   $ (10,227 )    $ (3,566 )    $ (6,661 )    187 %

~~Three months ended September 30, 2020 compared to three months ended September 30, 2019~~


	Three months ended. December 31,
	2020			2019			$ Change			% Change
Revenues	$	5,103		$	3,259		$	1,844			57	%
Cost of sales		821			846			(25	)		-3	%

Gross profit		4,282			2,413			1,869			77	%

BARDA income		449			386			63			16	%
Operating expenses:
Sales and marketing expenses		3,600			3,972			(372	)		-9	%
General and administrative expenses		3,401			7,107			(3,706	)		-52	%
Research and development expenses		3,361			2,312			1,049			45	%

Total operating expenses		10,362			13,391			(3,029	)		-23	%

Operating loss		(5,631	)		(10,592	)		4,961			-47	%
Interest expense		3			9			(6	)		-67	%
Other income/(expense)		4			99			(95	)		-96	%

Loss before income taxes		(5,630	)		(10,502	)		4,872			-46	%
Income tax expense		11			—			11			100	%

Net loss	$	(5,641	)	$	(10,502	)	$	4,861			-46	%

Revenue of the RECELL System totaled $5.1 million for the three months ended ~~September 30,~~December 31, 2020, an increase of $1.8 million or ~~56%~~57% over the $3.3 million reported for the three months ended ~~September 30,~~December 31, 2019. Consistent with the prior year, the current quarter increase in sales occurred in the United States as a result of the September 2018 FDA approval and commencement of the U.S. national market launch of the RECELL System in January 2019. Gross margin for the three months ended ~~September 30,~~December 31, 2020 was ~~82%~~84% compared to ~~81%~~74% for the same period in ~~2019.~~2019, driven largely by the extension of the product’s shelf-life along with lower shipping costs and increased production at our Ventura facility.

BARDA income consisted of funding from the Biomedical Advanced Research and Development Authority (“BARDA”), under the Assistant Secretary for Preparedness and Response, within the U.S. Department of Health and Human Services, under ongoing USG Contract No. HHSO100201500028C. Under the BARDA grant, income of ~~$596,000~~$449,000 was recognized during the three months ended ~~September 30,~~December 31, 2020 compared to income of ~~$2.1~~$386,000 for the three months ended December 31, 2019. BARDA income increased as a result of associated pivotal trials for treatment of pediatric scald injuries.

Operating costs for the three months ended December 31, 2020 totaled $10.4 million, a $3.0 million or 23% decrease as compared to the $13.4 million incurred during the three months ended December 31, 2019. Sales and marketing expenses for the three months ended December 31, 2020 totaled $3.6 million a decrease of $372,000 or 9% as compared to the $4.0 million for the three months ended December 31, 2019. The decrease in sales and marketing expenses is primarily due to lower travel expenses and conferences due to COVID-19 related to travel restrictions and higher costs incurred in the prior year associated with the product launch. General and administrative expenses totaled $3.4 million for the three months ended December 31, 2020, a decrease of $3.7 million or 52% as compared to the $7.1 million recognized during the three months ended December 31, 2019. The decrease was primarily related to a decrease in travel expenses due to COVID-19 travel restrictions , a decrease in legal costs and a decrease to share-based compensation due to the reversal of previously recognized expense for unvested awards related to the resignation of an executive officer in the current quarter. Research and development expenses for the three months ended December 31, 2020 totaled $3.4 million, an increase of $1.0 million or 45% over the $2.3 million recognized during the three months ended December 31, 2019. The increase was primarily attributed to ramping up clinical trials for treatment of vitiligo and pediatric scald injuries and other research and development costs associated with furthering the Company’s pipeline.

Net loss for the three months ended December 31, 2020 was $5.6 million, a decrease of $4.9 million or 46% compared to the loss of $10.5 million recognized during the three months ended December 31, 2019. The decrease in net loss was driven by the lower operating costs described above, partially offset by the higher revenue during the three months ended December 31, 2020.

Results of Operations for the six months ended December 31, 2020 compared to the six months ended December 31, 2019.

The table below summarizes the results of our continuing operations for each of the periods presented (in thousands).


	Six Months ended December 31,
	2020			2019			$ Change			% Change
Revenues	$	10,163		$	6,509		$	3,654			56	%
Cost of sales		1,750			1,465			285			19	%

Gross profit		8,413			5,044			3,369			67	%

BARDA income		1,045			2,437			(1,392	)		-57	%
Operating expenses:
Sales and marketing expenses		6,865			7,071			(206	)		-3	%
General and administrative expenses		11,703			10,529			1,174			11	%
Research and development expenses		6,735			4,131			2,604			63	%

Total operating expenses		25,303			21,731			3,572			16	%

Operating loss		(15,845	)		(14,250	)		(1,595	)		11	%
Interest expense		10			20			(10	)		-50	%
Other income/(expense)		8			202			(194	)		-96	%

Loss before income taxes		(15,847	)		(14,068	)		(1,779	)		13	%
Income tax expense		21			—			21			100	%

Net loss	$	(15,868	)	$	(14,068	)	$	(1,800	)		13	%

Revenue of the RECELL System totaled $10.2 million for the six months ended December 31, 2020, an increase of $3.7 million or 56% over the $6.5 million reported for the six months ended December 31, 2019. Consistent with the prior year, the increase in sales occurred in the United States as a result of the September ~~30,~~2018 FDA approval and commencement of the U.S. national market launch of the RECELL System in January 2019. Gross margin for the six months ended December 31, 2020 was 83% compared to 77% for the same period in 2019, driven largely by the extension of the product’s shelf-life along with lower shipping costs and increased production at our Ventura facility.

BARDA income consisted of funding from the Biomedical Advanced Research and Development Authority (“BARDA”), under the Assistant Secretary for Preparedness and Response, within the U.S. Department of Health and Human Services, under ongoing USG Contract No. HHSO100201500028C. Under the BARDA grant, income of $1.0 million was recognized during the six months ended December 31, 2020 compared to income of $2.4 million for the six months ended December 31, 2019. BARDA arrangement declined as a result of wind-down of certain activities associated with supporting the U.S. FDA approval of the RECELL System as well as the compassionate use and continued access ~~programs.~~programs and was partially offset by associated pivotal trials for treatment of pediatric scald injuries.

Operating costs for the ~~year~~six months ended ~~September 30,~~December 31, 2020 totaled ~~$14.9~~$25.3 million, a ~~$6.6~~$3.6 million or ~~79%~~16% increase over the ~~$8.3~~$21.7 million incurred during the ~~three~~six months ended ~~September 30,~~December 31, 2019. Sales and marketing expenses for the ~~three~~six months ended ~~September 30,~~December 31, 2020 totaled ~~$2.9~~$6.9 million ~~and were flat~~a decrease of $206,000 or 3% as compared to the ~~three~~$7.1 million for the six months ended ~~September 30,~~December 31, 2019. The decrease in sales and marketing expenses is primarily due to lower travel and conferences expenses due to COVID-19 related to travel restrictions and higher costs incurred in the prior year associated with the product launch. General and administrative expenses totaled ~~$5.5~~$11.7 million for the ~~three~~six months ended ~~September 30,~~December 31, 2020, an increase of ~~$2.5~~$1.2 million or ~~80%~~11% over the ~~$3.1~~$10.5 million recognized during the ~~three~~six months ended ~~September 30,~~December 31, 2019. The increase was driven by the Company’s status as a cross listed entity on NASDAQ and the ASX, one-time professional ~~services~~service costs ~~associated~~ with ~~establishing~~an executive employee, partially offset by lower travel expenses due to COVID-19 restrictions, a decrease in legal costs and a decrease to share-based compensation due to the ~~Company as a domestic filer with~~reversal of previously recognized expense for unvested awards related to the ~~SEC following completion~~resignation of an executive officer in the ~~Redomiciliation, and severance costs associated with a former executive employee.~~current quarter. Research and development expenses for the ~~three~~six months ended ~~September 30,~~December 31, 2020 totaled ~~$3.2~~$6.7 million, an increase of ~~$1.6~~$2.6 million or ~~96%~~63% over the ~~$1.6~~$4.1 million recognized during the ~~three~~six months ended ~~September 30,~~December 31, 2019. The increase was primarily attributed to ~~the commencement of pivotal~~ramping up clinical trials for treatment of vitiligo and pediatric scald injuries ~~soft tissue reconstruction, treatment of vitiligo~~ and other research and development activities to further promote the RECELL device. Share based compensation also increased to $3.2 million for the three months ended September 30, 2020, an increase of $2.5 million or 386% over the $672,000 recognized during the three months ended September 30, 2019. The increase was primarily driven by an increase in awards granted alongcosts associated with ~~the increase in grant fair value. The increase in the grant date fair value of the awards is due to the increase in~~furthering the Company’s ~~stock price compared to the prior year.~~pipeline.

Net loss for the ~~three~~six months ended ~~September 30,~~December 31, 2020 was ~~$10.2~~$15.9 million, an increase of ~~$6.6~~$1.8 million or ~~187%~~13% over the ~~$3.6~~$14.1 million recognized during the ~~three~~six months ended ~~September 30,~~December 31, 2019. The increase in net loss was driven by the higher operating costs described above, partially offset by the higher revenue during the ~~three~~six months ended ~~September 30,~~December 31, 2020. As a result of the U.S. national launch of the RECELL System in January 2019, and the expansion of research and development including multiple pivotal clinical studies seeking premarket approval from the FDA, operating expenses are expected to increase in future periods. These expenses are expected to be partially offset by increased commercial sales of the RECELL System.

Liquidity and Capital Resources

We expect to utilize cash reserves until U.S. sales of our products reach a level sufficient to fund ongoing ~~operations.~~operations for at least the next twelve months. The AVITA Group has historically funded its research and development activities, and more recently its substantial investment in sales and marketing activities, through raising capital by issuing securities, and it is expected that similar funding will be obtained to provide working capital if and when required. If the Company is unable to raise capital in the future, the Company may need to curtail expenditures by scaling back certain research and development or other programs.

The following table summarizes our cash flows for the periods ~~presented:~~presented (in thousands):


	Three Months Ended September 30,						Six Months ended December 31,
(In Thousands)	2020			2019
							2020			2019
Net cash used in operations	$	(7,713	)	$	(4,881	)	$	(13,388	)	$	(9,534	)
Net cash used in investing activities		(296	)		(152	)		(635	)		(246	)
Net cash used in financing activities		(4	)		(17	)
Net cash provided/(used) in financing activities								(9	)		76,840
Effect of foreign exchange rate on cash and restricted cash		127			(22	)		158			26
Net decrease in cash and restricted cash		(7,886	)	��	(5,072	)
Net increase (decrease) in cash and restricted cash								(13,874	)		67,086
Cash and restricted cash at beginning of the period		73,840			20,374			73,840			20,374
Cash and restricted cash at end the period		65,954			15,302			59,966			87,460

~~Three~~Six Months Ended ~~September 30,~~December 31, 2020, and ~~2019~~2019.

Net cash used in operating activities was ~~$7.7~~$13.4 million and ~~$4.9~~$9.5 million during the ~~three~~six months ended ~~September 30,~~December 31, 2020 and 2019, respectively. The increase was primarily due to higher operating costs associated with the ~~Company’s~~expansion of research and development activities, and the status asof being a cross listed entity on ~~NASDAQ and the ASX, the commercialization of the RECELL System in the United States, and the expansion of research and development activities.~~NASDAQ.

Net cash used in investing activities was ~~$296,000~~$635,000 and ~~$152,000~~$246,000 during the ~~three~~six months ended ~~September 30,~~December 31, 2020 and 2019, respectively. Cash flows used for investing activities was primarily attributable to payments for the purchase of a property and equipment.

Net cash ~~used~~provided by (used by) financing activities was ~~$4,000~~$(9,000) and ~~$17,000~~$76,840 for the ~~three~~six months ended ~~September 30,~~December 31, 2020 and 2019, respectively, and related to principal repayment of a finance ~~lease.~~lease in the current year and proceeds from the private placement in the prior year.

Capital ~~management~~management.

We aim to manage capital so that the Company continues as a going concern while also maintaining optimal returns to stockholders and benefits for other stakeholders. We also aim to maintain a capital structure that ensures the lowest cost of capital available to the Company. We regularly review the Company’s capital structure and seek to take advantage of available opportunities to improve outcomes for the Company and its stockholders.

For the three months ended ~~September 30,~~December 31, 2020, there were no dividends paid and we have no plans to commence the payment of dividends. We have no committed plans to issue further shares on the market but will continue to assess market conditions and the Company’s cash flow requirements to ensure the Company is appropriately funded in order to pursue its various opportunities. There is no significant external borrowing at the reporting date. Neither the Company nor any of the subsidiaries are subject to externally imposed capital requirement.

Based on the foregoing, we believe that our existing and future resources and revenues generated from operations and current level of expenses from operations to be sufficient to satisfy our working capital requirements for at least the next 12 months.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements (as defined in the rules and regulations of the SEC) that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material investors.

Commitments and Contractual Obligations

Our contractual obligations consist of operating leases as described in Footnote 4. During November 2020, the Company remeasured the lease liability for an office lease due to a change in the lease term. In addition to the modification for the office lease, the Company entered into a new lease in November 2020 for additional warehouse space.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Financial instruments ~~which~~that potentially subject us to concentrations of credit risk consist primarily of cash. We maintain cash in three financial institutions. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists. We perform periodic evaluations of the relative credit standing of these institutions.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and our Chief Financial Officer evaluated, with the participation of our management, the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. As of ~~September 30,~~December 31, 2020, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures, as defined in Securities Exchange Act Rule 13a-15(e) and 15d-15(e), were effective.

Our disclosure controls and procedures have been formulated to ensure (i) that information that we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934 ~~were~~was recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms and (ii) that the information required to be disclosed by us is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

Changes in Internal Controls over Financial Reporting

There was no change in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the ~~first~~second quarter of fiscal year 2021 covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that many of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the impact of the COVID-19 situation on our internal controls to minimize ~~the impact~~any undesirable effect on ~~their~~control design and operating effectiveness.

Part II - Other Information

Item 1.

LEGAL PROCEEDINGS

None.

Item 1A.

Risk Factors

~~None.~~Refer to “COVID-19 Business Update and Risks Associated with COVID-19” in Part 1 above.

Item 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

~~None~~None.

Item 3.

DEFAULTS UPON SENIOR SECURITIES

~~None~~None.

Item 4.

MINE SAFETY DISCLOSURES

Not applicable.

Item 5.

OTHER INFORMATION

None

Item 6.

EXHIBITS

(a) The following exhibits are filed as part of the Quarterly Report on Form 10-Q:


Exhibit No.		Description

3.1*		Amendment to Certificate of Incorporation

31.1		Rule 13a-14(a) Certification of Chief Executive Officer

31.2		Rule 13a-14(a) Certification of Chief Financial Officer

32		18 U.S.C. Section 1350 Certifications

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema

101.CAL		XBRL Taxonomy Extension Calculation Linkbase

101.DEF		XBRL Taxonomy Extension Definition Linkbase

101.LAB		XBRL Taxonomy Extension Label Linkbase

101.PRE		XBRL Taxonomy Extension Presentation Linkbase

*	Incorporated by reference to Exhibit 3.1 to Form 8-K of the Registrant filed December 2, 2020

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Date: ~~November 10, 2020~~	February 16, 2021	AVITA ~~THERAPEUTICS,~~MEDICAL, INC.

		By:	/s/ Dr. Michael Perry
			Dr. Michael Perry
			President and Chief Executive Officer
			(Principal Executive Officer)

		By:	/s/ Sean Ekins
			Sean Ekins
			Sr. VP of Finance
			(Interim Principal Financial and Accounting Officer)

2530


	Three Months Ended September 30, 2019
	Common Stock
	Shares		Amount		Additional Paid-in- Capital		Accumulated Other Comprehensive Income (Loss)			Accumulated Deficit			Total Shareholders’ Equity
Balance at June 30, 2019		18,712,996	$	3	$	165,473	$	8,184		$	(152,828	)	$	20,832

Net loss		—		—		—		—			(3,566	)		(3,566	)
Share-based compensation		—		—		672		—			—			672
Issuance of common stock to director in lieu of directors fees		15,853		—		107		—			—			107
Beginning balance adjustment related ot the adoption of ASC 842		—		—		—		—			(55	)		(55	)
Translation loss		—		—				(34	)		—			(34	)

Balance at September 30, 2019		18,728,849	$	3	$	166,252	$	8,150		$	(156,449	)	$	17,956

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company